{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:50:06Z","timestamp":1788522606872,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04171-9","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:05:09Z","timestamp":1767787509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a"],"prefix":"10.1186","volume":"24","author":[{"given":"Peng","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"3","key":"4171_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.hoc.2021.02.004","volume":"35","author":"H Ahmadi","year":"2021","unstructured":"Ahmadi H, Duddalwar V, Daneshmand S. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2021;35(3):531\u201341.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"4171_CR2","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, et al. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221\u201331.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"4171_CR3","doi-asserted-by":"publisher","first-page":"1519103","DOI":"10.3389\/fonc.2025.1519103","volume":"15","author":"RA Assal","year":"2025","unstructured":"Assal RA, Rashwan HH, Zakaria ZI, Sweillam JH, Fouda YM, Abdelhamid AM, et al. Deciphering the mysteries of MEG3 LncRNA and its implications in genitourinary cancers. Front Oncol. 2025;15:1519103.","journal-title":"Front Oncol"},{"issue":"1","key":"4171_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12885-023-10828-z","volume":"23","author":"P Hui","year":"2023","unstructured":"Hui P, Ni F, Zheng L, Jia L, Wang Z. Identification of immunotherapy-related LncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer. BMC Cancer. 2023;23(1):355.","journal-title":"BMC Cancer"},{"issue":"5","key":"4171_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.urolonc.2022.11.003","volume":"41","author":"E Morton","year":"2023","unstructured":"Morton E, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, et al. Urothelial carcinoma of the bladder with isolated lymph node metastasis: natural history and outcomes following surgical resection. Urol Oncol. 2023;41(5):255. e7- e14.","journal-title":"Urol Oncol"},{"issue":"10364","key":"4171_CR6","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comperat","year":"2022","unstructured":"Comperat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712\u201321.","journal-title":"Lancet"},{"issue":"7679","key":"4171_CR7","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/551S33a","volume":"551","author":"M Grayson","year":"2017","unstructured":"Grayson M. Bladder cancer. Nature. 2017;551(7679):S33.","journal-title":"Nature"},{"issue":"1","key":"4171_CR8","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1186\/s12885-024-12683-y","volume":"24","author":"S Botrous","year":"2024","unstructured":"Botrous S, Elmaghraby A, Achy SE, Mustafa Y, Abdel-Rahman S. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A. BMC Cancer. 2024;24(1):971.","journal-title":"BMC Cancer"},{"issue":"5","key":"4171_CR9","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1097\/JS9.0000000000002349","volume":"111","author":"Z Bi","year":"2025","unstructured":"Bi Z, Zhang Y, Song XR, Zheng WH, Chen P, Qiu PF, et al. Identification of biomarkers of shrinkage modes after neoadjuvant therapy in HER-2 positive breast cancer. Int J Surg. 2025;111(5):3677\u201384.","journal-title":"Int J Surg"},{"key":"4171_CR10","doi-asserted-by":"crossref","unstructured":"Park EG, Pyo SJ, Cui Y, Yoon SH, Nam JW. Tumor immune microenvironment LncRNAs. Brief Bioinform. 2022;23(1):bbab504.","DOI":"10.1093\/bib\/bbab504"},{"issue":"1","key":"4171_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13046-019-1132-0","volume":"38","author":"W Wu","year":"2019","unstructured":"Wu W, Yu T, Wu Y, Tian W, Zhang J, Wang Y. The miR155HG\/miR-185\/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019;38(1):133.","journal-title":"J Exp Clin Cancer Res"},{"key":"4171_CR12","doi-asserted-by":"publisher","first-page":"153994","DOI":"10.1016\/j.prp.2022.153994","volume":"237","author":"Z Han","year":"2022","unstructured":"Han Z, Tian Y, Liu Q, Zhao Y, Ji S, Zhang H, et al. LncRNA PTAR activates the progression of bladder cancer by modulating miR-299-3p\/CD164 axis. Pathol Res Pract. 2022;237:153994.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"4171_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1615\/CritRevEukaryotGeneExpr.2023048011","volume":"34","author":"Y Hong","year":"2024","unstructured":"Hong Y, Li Z, Su Y, Pu H, Zhang X. The CeRNA mechanism of LncRNA MEG3\/miR-21-5p\/SPRY2 in cell proliferation and apoptosis in bladder cancer. Crit Rev Eukaryot Gene Expr. 2024;34(1):55\u201368.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"4171_CR14","doi-asserted-by":"publisher","first-page":"117254","DOI":"10.1016\/j.lfs.2020.117254","volume":"243","author":"J Wang","year":"2020","unstructured":"Wang J, Li Z, Wang X, Ding Y, Li N. The tumor suppressive effect of long non-coding RNA FRMD6-AS2 in Uteri corpus endometrial carcinoma. Life Sci. 2020;243:117254.","journal-title":"Life Sci"},{"key":"4171_CR15","doi-asserted-by":"crossref","unstructured":"Liang L, Xia W, Yao L, Wu Q, Hua L, Cheng G, et al. Long non-coding RNA profile study identifies an immune-related LncRNA prognostic signature for prostate adenocarcinoma. Int Immunopharmacol. 2021;101(Pt A):108267.","DOI":"10.1016\/j.intimp.2021.108267"},{"key":"4171_CR16","doi-asserted-by":"crossref","unstructured":"Li F, Guo H, Liu B, Liu N, Xu Z, Wang Y, et al. Explore prognostic biomarker of bladder cancer based on competing endogenous network. Biosci Rep. 2020;40(12):BSR20202463.","DOI":"10.1042\/BSR20202463"},{"key":"4171_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms21197288","volume":"21","author":"V Holubekova","year":"2020","unstructured":"Holubekova V, Kolkova Z, Grendar M, Brany D, Dvorska D, Stastny I, et al. Pathway analysis of selected Circulating MiRNAs in plasma of breast cancer patients: A preliminary study. Int J Mol Sci. 2020;21:19.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4171_CR18","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1007\/s11033-018-4399-x","volume":"45","author":"R Said","year":"2018","unstructured":"Said R, Garcia-Mayea Y, Trabelsi N, Setti Boubaker N, Mir C, Blel A, et al. Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in prostate cancer Tunisian patients. Mol Biol Rep. 2018;45(6):2345\u201358.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"4171_CR19","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s11255-023-03666-2","volume":"55","author":"M Kaba","year":"2023","unstructured":"Kaba M, Pirincci N, Demir M, Kaba S, Oztuzcu S, Verep S. The relationship between MicroRNAs and bladder cancer: are MicroRNAs useful to predict bladder cancer in suspicious patients? Int Urol Nephrol. 2023;55(10):2483\u201391.","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"4171_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.hoc.2014.10.013","volume":"29","author":"M Sun","year":"2015","unstructured":"Sun M, Trinh QD. Diagnosis and staging of bladder cancer. Hematol Oncol Clin North Am. 2015;29(2):205\u201318. vii.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4171_CR21","doi-asserted-by":"publisher","first-page":"972558","DOI":"10.3389\/fonc.2023.972558","volume":"13","author":"X Xiong","year":"2023","unstructured":"Xiong X, Chen C, Li X, Yang J, Zhang W, Wang X, et al. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Front Oncol. 2023;13:972558.","journal-title":"Front Oncol"},{"issue":"2","key":"4171_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/jcmm.13986","volume":"23","author":"X Rui","year":"2019","unstructured":"Rui X, Wang L, Pan H, Gu T, Shao S, Leng J. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2\/miR-298\/CDK9 axis. J Cell Mol Med. 2019;23(2):865\u201376.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"4171_CR23","first-page":"1012","volume":"23","author":"HL Cao","year":"2019","unstructured":"Cao HL, Liu ZJ, Huang PL, Yue YL, Xi JN. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci. 2019;23(3):1012\u201321.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"4171_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41388-020-01548-w","volume":"40","author":"J Haldrup","year":"2021","unstructured":"Haldrup J, Strand SH, Cieza-Borrella C, Jakobsson ME, Riedel M, Norgaard M, et al. FRMD6 has tumor suppressor functions in prostate cancer. Oncogene. 2021;40(4):763\u201376.","journal-title":"Oncogene"},{"issue":"7","key":"4171_CR25","doi-asserted-by":"publisher","first-page":"11156","DOI":"10.1002\/jcp.27764","volume":"234","author":"H Xie","year":"2019","unstructured":"Xie H, Huang H, Huang W, Xie Z, Yang Y, Wang F. LncRNA miR143HG suppresses bladder cancer development through inactivating Wnt\/beta-catenin pathway by modulating miR-1275\/AXIN2 axis. J Cell Physiol. 2019;234(7):11156\u201364.","journal-title":"J Cell Physiol"},{"issue":"24","key":"4171_CR26","doi-asserted-by":"publisher","first-page":"25547","DOI":"10.18632\/aging.104162","volume":"12","author":"C Tang","year":"2020","unstructured":"Tang C, Cai Y, Jiang H, Lv Z, Yang C, Xu H, et al. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p\/TNS1 axis. Aging. 2020;12(24):25547\u201363.","journal-title":"Aging"},{"key":"4171_CR27","doi-asserted-by":"crossref","unstructured":"Huang CS, Tsai CH, Yu CP, Wu YS, Yee MF, Ho JY, et al. Long noncoding RNA LINC02470 sponges MicroRNA-143-3p and enhances SMAD3-Mediated Epithelial-to-Mesenchymal transition to promote the aggressive properties of bladder cancer. Cancers (Basel). 2022;14(4):968.","DOI":"10.3390\/cancers14040968"},{"issue":"12","key":"4171_CR28","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/carcin\/bgac087","volume":"43","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu T, Cheng C, Wang J, Wang C, Huang H, et al. LncRNA GAS5 regulates the Wnt\/beta-catenin pathway through the miR-18a-5p\/AXIN2\/GSK3beta axis to inhibit the proliferation and migration of bladder cancer cells. Carcinogenesis. 2022;43(12):1176\u201389.","journal-title":"Carcinogenesis"},{"issue":"1","key":"4171_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2017.99","volume":"18","author":"E Anastasiadou","year":"2018","unstructured":"Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"3\u20134","key":"4171_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41417-020-00211-6","volume":"28","author":"Y Li","year":"2021","unstructured":"Li Y, Shi B, Dong F, Zhu X, Liu B, Liu Y. LncRNA KCNQ1OT1 facilitates the progression of bladder cancer by targeting MiR-218-5p\/HS3ST3B1. Cancer Gene Ther. 2021;28(3\u20134):212\u201320.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"4171_CR31","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.bbamcr.2017.08.001","volume":"1864","author":"M Lv","year":"2017","unstructured":"Lv M, Zhong Z, Huang M, Tian Q, Jiang R, Chen J. LncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1887\u201399.","journal-title":"Biochim Biophys Acta Mol Cell Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04171-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04171-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04171-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:19:12Z","timestamp":1768465152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04171-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04171-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by The Ethics Committee of Huanggang Central Hospital and followed the principles outlined in the Declaration of Helsinki. In addition, informed consent has been obtained from the participants involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}